


All Wales Medicines Strategy Group

Grŵp Strategaeth Meddyginiaethau Cymru Gyfan



## **AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA142)**

### **NICE GUIDANCE ISSUED MAY 2008**

(Refer to NICE website for full guidance on NICE recommendations,  
including any specific restrictions on the use of the technology)

### **Darbepoetin alfa (Aranesp<sup>®</sup>)**

**For the treatment of symptomatic anaemia in adult  
cancer patients with non-myeloid malignancies  
receiving chemotherapy**

**Amgen Ltd**

**March 2004**

Darbepoetin alfa (Aranesp<sup>®</sup>) is indicated for the treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy.

AWMSG appraised darbepoetin alfa (Aranesp<sup>®</sup>) during the December 2003 meeting and the decision was not to support the use of erythropoietin in the treatment of anaemia associated with cancer due to the lack of evidence of cost-effectiveness.

[See AWMSG December 2003 meeting minutes for further information.](#)